SAN FRANCISCO, Oct. 16, 2018 /PRNewswire-PRWeb/ — uBiome, the leader in microbial genomics, announces the addition of Dr. Isabel Moreno-Indias, PhD, Senior Researcher at the Biomedical Research Institute of Malaga, University Hospital Virgen of Victoria, Malaga and Center for Biomedical Research in the Physiopathology Network of Obesity and Nutrition, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Moreno-Indias will bring to uBiome knowledge of the microbiota in patients with metabolic disorders, especially obesity and metabolic syndrome. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Moreno-Indias is an outstanding researcher at the intersection of microbiota, obesity, and nutrition,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are honored to include her on our advisory board and look forward to her future insights in the field.”

Dr. Moreno-Indias’ central field of study is metabolic disorders. She is a senior researcher at the Biomedical Research Institute of Malaga, the University Hospital Virgen of Victoria in Malaga, and the Center for Biomedical Research in the Physiopathology Network of Obesity and Nutrition in Spain. Dr. Moreno-Indias is a former Guest Researcher at the University of Copenhagen Department of Veterinary Disease Biology and has has published 54 research articles.

About joining uBiome’s Scientific Advisory Board, Dr. Moreno-Indias said, “I am very happy to join this amazing advisory board and hope to build a perfect symbiosis with a company pioneering in the microbiome. Together, we can advance the knowledge of the central role of this new organ with the homeostasis of the host and translate it for patients.”

In addition to Dr. Moreno-Indias, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

SOURCE Ubiome